Medical professionals are getting closer to developing a risk biomarker that will let them know which of their paediatric stem cell transplant patients are most likely to have sinusoidal obstruction syndrome (SOS), a potentially lethal side effect.
Doctors are one step closer to establishing a risk biomarker that will warn them as to which of their paediatric stem cell transplant patients are likely to encounter sinusoidal obstruction syndrome (SOS), a potentially fatal side effect.